atai Beckley doses the last patient in the VLS-01 Phase 2b study for treatment-resistant depression and plans topline results in the first half of 2025

VLS-01, an intranasal DMT candidate for treatment-resistant depression, has reached the last-patient-dosed milestone in its Phase 2b clinical study. atai Beckley expects topline efficacy and safety results in the first half of 2025, marking a key step in the program's mid-stage development. The study focuses on people with depression that has not responded adequately to standard treatments. Intranasal delivery is central to the product design, aiming to make DMT administration more practical and clinically scalable while preserving a rapid psychedelic intervention model. The milestone signals continued commercial and clinical momentum in psychedelic drug development. If the readout is positive, VLS-01 could strengthen the case for short-acting psychedelic therapies within mainstream mental health care and support later-stage trials.